Total Payments
$25,364
2024 Payments
$718.06
Companies
62
Transactions
437
Medicare Patients
38,284
Medicare Billing
$11.3M
Payment Breakdown by Category
Research$15,822 (62.4%)
Food & Beverage$5,869 (23.1%)
Consulting$3,458 (13.6%)
Education$214.16 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15,822 | 9 | 62.4% |
| Food and Beverage | $5,869 | 411 | 23.1% |
| Consulting Fee | $3,458 | 2 | 13.6% |
| Education | $214.16 | 15 | 0.8% |
Payments by Type
Research
$15,822
9 transactions
General
$9,542
428 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $15,822 | 9 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $3,910 | 33 | $0 (2024) |
| Janssen Biotech, Inc. | $894.60 | 88 | $0 (2023) |
| PFIZER INC. | $773.15 | 75 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $442.89 | 31 | $0 (2024) |
| GlaxoSmithKline, LLC. | $275.60 | 17 | $0 (2024) |
| Genentech USA, Inc. | $260.93 | 16 | $0 (2023) |
| Amgen Inc. | $222.01 | 12 | $0 (2022) |
| Merck Sharp & Dohme LLC | $216.88 | 17 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $167.64 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $718.06 | 33 | GlaxoSmithKline, LLC. ($200.96) |
| 2023 | $4,008 | 36 | E.R. Squibb & Sons, L.L.C. ($3,458) |
| 2022 | $741.37 | 31 | Eli Lilly and Company ($148.00) |
| 2021 | $1,212 | 44 | Eli Lilly and Company ($383.10) |
| 2020 | $850.64 | 13 | Eli Lilly and Company ($647.40) |
| 2019 | $7,957 | 99 | Eli Lilly and Company ($6,706) |
| 2018 | $8,529 | 90 | Eli Lilly and Company ($7,550) |
| 2017 | $1,348 | 91 | Eli Lilly and Company ($386.74) |
All Payment Transactions
437 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $26.44 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $29.32 | General |
| Category: Oncology | ||||||
| 11/26/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $10.24 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $26.58 | General |
| Category: Oncology | ||||||
| 11/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.68 | General |
| Category: Oncology | ||||||
| 11/11/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $7.99 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $8.36 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $81.10 | General |
| Category: Hematology | ||||||
| 09/16/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $22.14 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.42 | General |
| Category: Hematology | ||||||
| 09/04/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $33.79 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $10.36 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.63 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $7.07 | General |
| Category: ONCOLOGY | ||||||
| 06/25/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $30.60 | General |
| Category: ONCOLOGY | ||||||
| 06/25/2024 | Sirtex Medical Inc | SIR-Spheres Microspheres (Device) | Food and Beverage | Cash or cash equivalent | $29.64 | General |
| Category: Interventional Oncology | ||||||
| 06/18/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $7.15 | General |
| Category: ONCOLOGY | ||||||
| 06/12/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $26.96 | General |
| Category: Oncology | ||||||
| 05/17/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $27.34 | General |
| Category: NONE | ||||||
| 05/09/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: ONCOLOGY | ||||||
| 04/17/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $15,655 | 8 |
| A SINGLE-ARM, GLOBAL, PHASE 4 STUDY OF ABEMACICLIB, A CDK 4 & 6 INHIBITOR, IN COMBINATION WITH NONSTEROIDAL AROMATASE INHIBITORS (ANASTROZOLE OR LETROZOLE) IN PARTICIPANTS WITH HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE ADVANCED BREAST CANCER WITH POOR PROGNOSTIC FACTORS | Eli Lilly and Company | $167.14 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 87 | 7,776 | 179,394 | $5.2M | $2.0M |
| 2022 | 99 | 10,227 | 249,089 | $8.8M | $3.1M |
| 2021 | 103 | 10,400 | 262,986 | $8.0M | $3.2M |
| 2020 | 94 | 9,881 | 293,802 | $7.6M | $3.1M |
Total Patients
38,284
Total Services
985,271
Medicare Billing
$11.3M
Procedure Codes
383
All Medicare Procedures & Services
383 procedure records from CMS Medicare Utilization — Page 1 of 16
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 29 | 12,200 | $1.3M | $526,802 | 39.1% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 15 | 8,960 | $519,680 | $212,672 | 40.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 63 | 10,680 | $304,914 | $193,687 | 63.5% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 32 | 4,820 | $296,093 | $171,465 | 57.9% |
| J1930 | Injection, lanreotide, 1 mg | Office | 2023 | 12 | 3,240 | $302,422 | $140,648 | 46.5% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 11 | 3,420 | $299,934 | $129,300 | 43.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 642 | 820 | $135,300 | $75,296 | 55.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 93 | 84,000 | $252,000 | $73,411 | 29.1% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 13 | 5,200 | $81,952 | $51,054 | 62.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 183 | 437 | $157,320 | $43,719 | 27.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 194 | 277 | $60,940 | $36,750 | 60.3% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 14 | 1,450 | $176,697 | $31,859 | 18.0% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 13 | 264 | $177,936 | $24,873 | 14.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 160 | 759 | $60,720 | $16,848 | 27.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 771 | 1,499 | $43,201 | $15,458 | 35.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 990 | 1,964 | $70,704 | $14,891 | 21.1% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 45 | 10,790 | $56,971 | $14,621 | 25.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 965 | 1,687 | $15,183 | $14,171 | 93.3% |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | Office | 2023 | 17 | 3,000 | $29,518 | $13,747 | 46.6% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 28 | 690 | $69,000 | $12,886 | 18.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 153 | 230 | $31,936 | $11,177 | 35.0% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 19 | 33 | $40,392 | $11,159 | 27.6% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 27 | 1,620 | $35,964 | $9,792 | 27.2% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 19 | 940 | $145,700 | $7,862 | 5.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 68 | 151 | $28,690 | $7,551 | 26.3% |
About Dr. Christopher Vaughn, M.D
Dr. Christopher Vaughn, M.D is a Hematology & Oncology healthcare provider based in Fredericksburg, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851322499.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Vaughn, M.D has received a total of $25,364 in payments from pharmaceutical and medical device companies, with $718.06 received in 2024. These payments were reported across 437 transactions from 62 companies. The most common payment nature is "" ($15,822).
As a Medicare-enrolled provider, Vaughn has provided services to 38,284 Medicare beneficiaries, totaling 985,271 services with total Medicare billing of $11.3M. Data is available for 4 years (2020–2023), covering 383 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Fredericksburg, VA
- Active Since 07/05/2006
- Last Updated 03/24/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1851322499
Products in Payments
- DARZALEX (Biological) $399.89
- OPDIVO (Biological) $281.16
- IMBRUVICA (Drug) $267.12
- IBRANCE (Drug) $216.21
- XTANDI (Drug) $204.66
- Erleada (Drug) $201.20
- KEYTRUDA (Biological) $152.55
- TASIGNA (Drug) $146.11
- JEMPERLI (Biological) $136.90
- Xermelo (Drug) $128.95
- XARELTO (Drug) $109.38
- REBLOZYL (Biological) $98.52
- Avastin (Biological) $93.89
- LYNPARZA (Drug) $91.66
- BOSULIF (Drug) $89.27
- INLYTA (Drug) $88.22
- OJJAARA (Drug) $86.19
- MYLOTARG (Biological) $79.75
- JEVTANA (Drug) $76.64
- LUTATHERA (Drug) $73.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fredericksburg
Dr. Sudeep Menachery, Md, MD
Hematology & Oncology — Payments: $43,555
Hematology & Oncology $43,555
Dr. Lakshminarayanan Nandagopal
Hematology & Oncology — Payments: $13,537
Hematology & Oncology $13,537
Dr. Charles Maurer, Md, MD
Hematology & Oncology — Payments: $12,694
Hematology & Oncology $12,694
Lisa Simmons, Md, MD
Hematology & Oncology — Payments: $10,038
Hematology & Oncology $10,038
Ms. Bonny Moore, Md, MD
Hematology & Oncology — Payments: $8,111
Hematology & Oncology $8,111
Mr. Andrew Tiu, M.d, M.D
Hematology & Oncology — Payments: $4,357
Hematology & Oncology $4,357